Lupin Limited — Updates, 17-03-2025: Press Release

Lupin Limited has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg. This product, to be manufactured at the Goa facility, is a bioequivalent to Catalyst Pharmaceuticals' Firdapse® Tablets, 10 mg, and treats Lambert-Eaton myasthenic syndrome in adults and children aged six and older. The global market for Amifampridine Tablets had an estimated net sale of USD 306 million for the fiscal year ending December 31, 2024. This approval positions Lupin favorably in the pharmaceutical sector, offering growth potential in the neuromuscular disorder treatment market. Investors should consider this development as a positive indicator of Lupin's strategic expansion and potential revenue growth.